Breakthrough Imaging in Hepatocellular Carcinoma - Wikidata - awgldk - TriplyDB

Breakthrough Imaging in Hepatocellular Carcinoma

Breakthrough Imaging in Hepatocellular Carcinoma

http://www.wikidata.org/entity/Q38969727

about

Breakthrough Imaging in Hepatocellular Carcinoma

http://www.wikidata.org/entity/Q38969727

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Breakthrough Imaging in Hepatocellular Carcinoma

@en

type

label

Breakthrough Imaging in Hepatocellular Carcinoma

@en

prefLabel

Breakthrough Imaging in Hepatocellular Carcinoma

@en

P1433

Q38969727-C2A52D6B-4E30-4B24-8AC1-44C60F9DF66C

P1476

Q38969727-F66AF90B-D021-4834-9B9F-4095A5E61EA7

P2093

Q38969727-0FCD47CF-7889-464A-930E-223B583D52F0

P2860

Q38969727-06D86460-313C-473D-B102-2D1D711229CD

Q38969727-18BD3DE0-2497-43C3-8F7E-E028C5F4AD7A

Q38969727-1F884AA2-7D70-4834-8CF9-A46A36EA6A44

Q38969727-20C64A2B-681E-469F-8780-2296CE678ABC

Q38969727-21FFA5DF-39BF-4442-A634-398965518EE4

Q38969727-22A1DF85-2D1D-450B-BACA-0E3D9D7C90F7

Q38969727-2DA52E36-83D6-4A19-AF62-12792680B9F8

Q38969727-31DD5B6D-D953-4DD9-96FC-5CED1D38C4ED

Q38969727-32FDC85D-6EF8-4F21-9D77-DAC2F05382DE

Q38969727-38FB9343-B40F-45F1-8637-6584A8C4F72D

P304

Q38969727-18C99BEE-FDA8-42A7-A9ED-20449598B1A7

P31

Q38969727-128f9908-b91e-4621-9d8a-60ef87875e5d

Q38969727-FAB15616-FC5E-4F19-B8CC-396BFA852725

P356

Q38969727-E2BC02C7-7667-4F64-B9AB-96A04928AD3B

P433

Q38969727-2AB86081-ABF1-4B96-AD16-C6021A44ACF1

P478

Q38969727-A27B143C-D313-4A59-AB40-780B9BFC90E7

P577

Q38969727-B3F9BF8F-5383-4921-9831-BA8C385F58F0

P698

Q38969727-CB714806-FEBA-4D77-9134-D65086A68B32

P932

Q38969727-45AF304A-3E91-49AC-BE2D-861CAE6256D1

P356

P1433

P1476

Breakthrough Imaging in Hepatocellular Carcinoma

@en

P2093

M Kudo

http://www.w3.org/2001/XMLSchema#string

P2860

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

Diagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current Consensus

Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.

Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images

Gadolinium ethoxybenzyl diethylenetriamine pentaacetic Acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma.

Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC.

Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.

How to define transarterial chemoembolization failure or refractoriness: a European perspective

Ultrasound fusion imaging of hepatocellular carcinoma: a review of current evidence.

Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles.

P304

47-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000367761

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26989659

http://www.w3.org/2001/XMLSchema#string

P932

4789879

http://www.w3.org/2001/XMLSchema#string